Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Viking Therapeutics (VKTX) over the last 4 years, with Q4 2018 value amounting to $12000.0.

  • Viking Therapeutics' Non-Current Deffered Revenue changed N/A to $12000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $12000.0, marking a year-over-year change of. This contributed to the annual value of $12000.0 for FY2018, which is N/A changed from last year.
  • As of Q4 2018, Viking Therapeutics' Non-Current Deffered Revenue stood at $12000.0.
  • In the past 5 years, Viking Therapeutics' Non-Current Deffered Revenue registered a high of $31239.0 during Q4 2015, and its lowest value of $6054.0 during Q2 2017.
  • In the last 4 years, Viking Therapeutics' Non-Current Deffered Revenue had a median value of $19149.0 in 2015 and averaged $18706.3.
  • As far as peak fluctuations go, Viking Therapeutics' Non-Current Deffered Revenue skyrocketed by 692.99% in 2016, and later plummeted by 7543.62% in 2017.
  • Viking Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $31239.0 in 2015, then tumbled by 47.8% to $16307.0 in 2016, then crashed by 62.87% to $6054.0 in 2017, then skyrocketed by 98.22% to $12000.0 in 2018.
  • Its Non-Current Deffered Revenue was $12000.0 in Q4 2018, compared to $6054.0 in Q2 2017 and $10862.0 in Q1 2017.